Education
About Us
Working with TipRanks
Follow Us
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
2696 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$13.60 - HK$29.20
Previous CloseN/A
Volume849.10K
Average Volume (3M)N/A
Market Cap
HK$14.92B
Enterprise ValueHK$16.08B
Total Cash (Recent Filing)¥824.87M
Total Debt (Recent Filing)¥687.91M
Price to Earnings (P/E)20.0
Beta0.47
Next Earnings
Mar 31, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.38
Shares Outstanding163,428,540
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Shanghai Henlius Biotech, Inc. Class H News
PremiumCompany Announcements
Shanghai Henlius Biotech’s HLX99 Receives FDA Approval for ALS Treatment
PremiumCompany Announcements
Shanghai Henlius Biotech Doses First Patient in Phase 2 HLX43 Trial
PremiumCompany Announcements
Shanghai Henlius Signs Licensing Deal with Dr. Reddy’s for Antibody Therapy
PremiumCompany Announcements
Shanghai Henlius Biotech Announces New Employee Representative Supervisor
PremiumCompany Announcements
Shanghai Henlius Biotech’s HLX11 BLA Accepted by FDA
PremiumCompany Announcements
Shanghai Henlius Biotech Remains Public as Merger Proposal Fails
PremiumCompany Announcements
Shanghai Henlius Biotech Confirms Qualification of Joint Company Secretary---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
― Other Institutional Investors
99.86% Public Companies and
Individual Investors
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$13.60 and its highest was HK$29.20 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$14.92B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Mar 31, 2025 which is in 27 days.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Shanghai Henlius Biotech, Inc. Class H released its earnings results on Aug 26, 2024. The company reported HK$0.758 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.758.
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Overvalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.758 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.655%.
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
---
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.40%
12-Months-Change
Fundamentals
Return on Equity
31.16%
Trailing 12-Months
Asset Growth
3.62%
Trailing 12-Months
2696 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
3SBio
―
Wuxi Biologics (Cayman)
―
Viva Biotech Holdings
―
Best Analysts Covering 2696
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+74.02%
reiterated a buy rating 10 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.02% per trade.
---